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Abstract 
Introduction 
Coagulation and complement systems are simultaneously activated at sites of tissue 
injury, leading to thrombin generation and opsonisation with C3b. Thrombomodulin 
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(TM) is a cell-bound regulator of thrombin activation, but can also enhance the 
regulatory activity of complement factor H (FH), thus accelerating the degradation of 
C3b into inactive iC3b. 
Objectives 
This study sought to determine the biophysical interaction affinities of two 
recombinant TM analogs with thrombin, FH and C3b in order to analyze their ability 
to regulate serum complement activity. 
Methods 
Surface plasmon resonance (SPR) analysis was used to determine binding affinities 
of TM analogs with FH and C3b, and compared to thrombin as positive control. The 
capacity of the two recombinant TM analogs to regulate complement in serum was 
tested in standard complement hemolytic activity assays.  
Results 
SPR analysis showed that both TM analogs bind FH with nanomolar and C3b with 
micromolar affinity; binding affinity for its natural ligand thrombin was several fold 
higher than for FH. At a physiological relevant concentration, TM inhibits 
complement hemolytic activity in serum via FH dependent and independent 
mechanisms. 
Conclusions  
TM exhibits significant binding affinity for complement protein FH and C3b-FH 
complex and its soluble form is capable at physiologically relevant concentrations of 
inhibiting complement activation in serum. 
Keywords 
Complement, thrombomodulin, hemolytic assay, Surface Plasmon Resonance 
Abbreviations 
AP, alternative pathway; CH50, the amount of serum (l) giving 50% hemolysis of 
sheep erythrocytes; CFD, complement fixation diluents buffer; CP, classical 
pathway; DIC, disseminated intravascular coagulation; EGF, endothelial growth 
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factor domain; FB, Factor B; FH-H50, the amount of functional FH needed to lyse 
50% ShEA; Factor H; FI, Factor I; HUS, hemolytic uremic syndrome; IC50, the 
concentration of an inhibitor where the response is reduced by 50%; LP, lectin 
pathway; MAC, membrane attack complex; NHS, normal human serum; PPACK, 
Phenylalanyl-propyl-arginine chloromethyl ketone; SCR, short consensus repeat; 
ShEA, Amboceptor-sensitized sheep erythrocytes; SPR, surface plasmon 
resonance; TAFI, thrombin-activatable fibrinolysis inhibitor TM, thrombomodulin;  
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1. Introduction 
Thrombomodulin (TM; CD141) [1, 2] is an integral membrane protein while 
heterogeneous soluble fragments of TM (sTM) are present in blood [3] and urine [4] 
and act as an effective marker of endothelial cell injury. Endotoxin and inflammatory 
cytokines decrease membrane-bound TM expression on the endothelium and 
increase soluble TM in blood [5], [6].  
TM’s role in haemostasis regulation is primarily to down-regulate thrombin 
generation [7]. The TM-thrombin complex converts protein C to activated protein C 
(APC), which in turn mediates inactivation of factors Va and VIIIa in the presence of 
protein S [8]. TM-thrombin complex also activates thrombin-activatable fibrinolysis 
inhibitor (TAFI) and hence down-regulates fibrinolysis [9]. Interestingly, TAFI 
inactivates C3a and C5a [10] revealing a central role for this molecule in the 
regulation and interface between complement and coagulation.   
Complement and coagulation are both innate blood defense systems, evolutionary 
linked with functional similarities and many shared structural motifs.  Crosstalk 
events between the complement and coagulation pathways have been investigated, 
but are as yet not comprehensively characterised [11, 12]. 
Complement protects against pathogens – primarily bacterial infection – by rapid 
activation of serine proteases and generation of active products. Cell killing is 
achieved directly through lytic pore formation (membrane attack complex; MAC), and 
indirectly via anaphylatoxins (C3a, C5a) and marking targets for phagocytosis 
(opsonisation; C3b, iC3b).  Complement is activated via three distinct pathways, 
triggered respectively by antibody (classical, CP), bacterial carbohydrate (mannose 
binding lectin, LP) or contact activation (alternative, AP). All pathways lead to 
enzymatic cleavage of complement C3 to the active fragments C3b and C3a. The 
opsonin C3b binds indiscriminately to pathogens and adjacent host cells. To prevent 
damage to self, complement is controlled by regulators, limiting complement 
activation by inactivating C3b, dissociating C3/C5 convertase enzymes or inhibiting 
MAC formation [13, 14]. The regulator factor H (FH) accelerates C3 convertase 
dissociation and acts as a co-factor for the factor I (FI)-mediated inactivation of C3b, 
regulating both in the fluid phase and on cell surfaces [15]. 
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TM appears to modulate complement activity by enhancing FH co-factor activity. TM 
co-precipitates with FH and C3b and both of these bind to the surface of TM-
expressing HEK293 cells. In fluid phase cleavage assays, TM enhances FH/FI-
mediated C3b inactivation in a dose-dependent manner [16, 17], although the 
molecular basis by which this occurs is incompletely understood.  
Complement and coagulation crosstalk in disease, and the potential therapeutic 
application of TM, is the subject of ongoing investigation. Recombinant human 
soluble TM (ART-123; Recomodulin™) has been investigated for treatment of 
disseminated intravascular coagulation (DIC) and sepsis-induced DIC [18, 19], and 
approved for treatment in Japan. Recently, studies have investigated the role of 
soluble TM in patients with hemolytic uremic syndrome (HUS) [20, 21] and atypical 
HUS (aHUS) [22]. aHUS has been associated with TM mutations [16], but is 
primarily linked to complement dysregulation caused by mutations in complement 
proteins [23-27] or autoantibodies [28, 29]. 
In this study, we utilize two human recombinant TM analogs generated in different 
expression systems, using SPR analysis to determine binding affinity for 
complement C3b and FH. We further test the capacity of TM to act as a complement 
regulator in serum. 
2. Materials and Methods 
2.1 Complement and coagulation components 
Complement factor H (FH) and factor B (FB) were affinity-purified from EDTA-
plasma of healthy volunteers on anti-FH (mAb 35H9, kind gift from Prof. Santiago 
Rodríguez de Cordoba, Madrid, Spain) or anti-Bb (mAb JC1, in-house) immobilized 
on HiTrap columns (GE Healthcare UK Limited, Amersham, UK). HRP-conjugated 
polyclonal anti-FH antibody was prepared in-house. Factor D (FD) and C3b were 
purchased from Complement Technology Inc (Tyler, Texas, USA). Polyclonal anti-
TM antibody and the two human recombinant soluble TM were from R & D Systems 
Europe Ltd (Abingdon, UK) and Abcam plc (Cambridge, UK); the first was produced 
in a mouse myeloma cell line (NS0-derived) with sequence: Ala19-Ser515, with C-
terminal 6-His-tag; TM1, the second was from HEK293 cells, sequence: Ala19-
Ala509; TM2. Phenylalanyl-propyl-arginine chloromethyl ketone (PPACK)-inhibited 
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thrombin and active thrombin were from Enzyme Research Laboratories Ltd 
(Swansea, UK). Recombinant S195A thrombin [30], a catalytically inactive mutant; 
and TM456, a recombinant fragment of TM comprising EGF 4-6 including the 
thrombin binding sites EGF5-6  [31], was a kind gift from Prof. J. A. Huntington 
(Cambridge University, UK). Rabbit thrombomodulin was purchased from 
Haematologic Technologies Inc (Vermont, USA), Complement fixation diluent (CFD) 
was from Oxoid Ltd (Basingstoke, UK),sheep erythrocytes from TCS Biosciences Ltd 
(Buckingham, UK) and Amboceptor from Siemens Healthcare GmbH (Erlangen, 
Germany). Thrombin generation assay reagents (platelet-poor-plasma reagent, 
fluorogenic substrate, thrombin calibration standard) were purchased from 
Thrombinoscope B.V. (Maastricht, Netherlands). Chromogenic substrate Biophen 
CS-21 for APC was from Cambridge Bioscience Ltd (Cambridge, UK). OPD and 
Chondroitinase ABC from Proteus vulgaris was from Sigma-Aldrich Company Ltd. 
(Gillingham, UK). Polystyrene plates (MaxiSorpTM) were from Fisher Scientific UK Ltd 
(Loughborough, UK) Biacore chips and reagents from GE Healthcare UK Limited 
(Amersham, UK). 
2.2 Generation of depleted sera for hemolysis assays 
Normal human serum (NHS) isolated from pooled whole blood of three healthy 
volunteers was sequentially affinity-depleted (ΔBH-NHS) on anti-Bb (mAb JC1, in-
house) and anti-FH (mAb 35H9) affinity columns in the presence of CFD buffer. FB, 
a key activator of the alternative pathway (AP), is depleted alongside FH to prevent 
consumption of complement due to spontaneous AP activation in the absence of FH; 
FB is added back immediately prior to assay activation (addition of activated ShEA).  
FH was quantified in the depleted serum using an in-house developed ELISA. In H-NHS (compared to NHS), FH was undetectable at standard serum dilution 
(1:3200) and even at 1:100 dilution no specific signal was observed above 
background - residual FH was <1.5ug/ml or <0.5% of average concentration in NHS. 
2.3 Mass spectrometry analysis of thrombomodulin analogs 
TM variants were subjected to mass spectrometry analysis (Applied Biosystems 
4800 MALDI TOF/TOF Analyser, CBS Cardiff) to determine the molecular weights of 
the TM analogs.  
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2.4 Anticoagulant function of thrombomodulin variants 
The anticoagulant function of TM in normal, platelet-poor, pooled plasma was 
assessed using a Fluoroskan Ascent plate reader (Thermo Lab System) by 
incubating 80 L of citrated plasma with 20 L of platelet-poor plasma reagent 
containing 5pM tissue factor (TF) and 4M phospholipids in the presence or absence 
of TM (5nM). Thrombin generation was initiated by automatic dispensation of 
fluorogenic thrombin substrate (FluCa) and determined using a thrombin calibration 
standard (T-Cal). Measurements were taken at short intervals for 162 minutes.  
Activated protein C (APC) was measured by adding varying concentrations of TM 
(2.5-10 nM) to a fixed concentration of thrombin (0.2 nM) and protein C (500 nM) in 
10 mM Hepes, 150 mM NaCl, 3 mM CaCl2, pH7.4 then incubated at 37°C for 2 
hours. Thrombin was inhibited by adding 1 ul (1U) Hirudin for 15 minutes at 37°C. 
APC-generation was measured by adding a chromogenic substrate (Biophen CS-
21), incubated for 10 minutes and colorimetric output read at 405 nm absorbance. 
2.5 Ligand binding assay of thrombomodulin to complement factor H 
TM (1 g/ml) or 10ug/ml TM456 was coated onto polystyrene plates in 50 l 
carbonate buffer, pH 9.6 for 2 hours at room temperature, blocked with 1% gelatine 
in phosphate buffered saline containing 0.1% Tween (PBST) and incubated with 
varying concentrations of FH (1-5 g/ml). Bound FH was detected using a HRP-
conjugated polyclonal anti-FH antibody (10g/ml), adding OPD substrate, stopped 
using 10% H2SO4 and absorbance read at 492 nm. Background (gelatine-only 
coated wells) was subtracted from the binding signal as blank. 
2.6 Surface plasmon resonance (SPR) binding interaction and affinity analysis 
All analyses were performed on a Biacore T100 (GE Healthcare) in Hepes buffered 
saline (HBS), 0.01% surfactant P20, pH 7.4. Kinetics were analyzed at 20l/min flow 
rate at 25°C. Due to its low isoelectric point, TM immobilization to a CM5 Biacore 
chip via standard amine coupling was not feasible. Therefore an indirect capture 
method was used, as described previously [32]. Briefly, polyclonal anti-TM antibody 
was immobilized via amine coupling to a CM5 chip at 2000RU, a density chosen to 
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ensure that a sufficient proportion of the captured molecules exposed a binding 
epitope. TM analogs were captured stably on the antibody surface on adjacent flow 
cells. Binding stability of the TM-antibody complex was assessed over time prior to 
analysis and shown to be sufficiently stable for use as a baseline surface for the 
duration of the analysis (data not shown). 
To measure binding kinetics of each interaction, complement FH, C3b or preformed 
C3b/FH complexes were flowed across captured TM at varying concentrations. 
PPACK-thrombin and S195A thrombin interaction with captured TM was tested as 
positive control. We used PPACK-inhibited and S195A thrombin to prevent non-
specific proteolysis during the analysis; as the active site is not directly involved in 
TM binding [33], inhibition should not interfere with affinity analysis. As a direct 
comparison to the Ca2+-independent C3b-FH interaction, all analyses were 
performed in the absence of Ca2+; the effect of Ca2+ removal on TM-thrombin 
interaction is documented [32]. The surface was regenerated with 10 mM sodium 
acetate pH 4, 1 M NaCl, this did not affect TM binding to the capture antibody. 
TM binding with C3b was also tested in the reverse orientation by flowing TM at 1 M over a 6000RU thioester-deposited C3b surface. A C3bBb convertase was 
formed in Hepes buffer saline pH 7.4, 1mM MgCl2 by flowing FB (200 g/ml) and FD 
(0.5 g/ml) over a 1000RU amine-coupled C3b surface; 200nM TM was flowed to 
test binding and TM impact on C3bBb decay/dissociation. As a positive control, FH 
(100 nM) was flowed over and decayed the convertase efficiently. The effect of TM 
on FH-mediated C3bBb decay was tested by simultaneously flowing 200nM TM and 
100nM FH over the C3bBb surface. 
2.7 Hemolysis assays 
2.7.1 Standard serum titration assay 
Hemolytic assays have traditionally been used to assess the functional activity of the 
complement system based on protocols first described by Mayer [34]. Serial dilutions 
of NHS were incubated with antibody (Amboceptor)-sensitized sheep erythrocytes 
(ShEA), resulting in complement-mediated lysis of the cells. To test complement 
regulation by TM, a fixed concentration of human recombinant TM was added to 
neat (100%) NHS before serially diluting the NHS in CFD and subsequent addition of 
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a 2% ShEA suspension in CFD buffer. The complement regulating ability of both TM 
analogs TM1 and TM2 was tested twice each on different days using NHS pooled 
from three healthy donors and freshly made ShEA suspension. 
Lysis was calculated by measuring hemoglobin release, control incubations were 
ShEA incubated in buffer only (0% lysis) or in 0.001% Triton X (100% lysis). 
Percentage hemolysis = 100 × (A410 test sample – A410 0% control)/(A410 100% 
control – A410 0% control). The resulting sigmoidal titration curves are expressed as 
% hemolysis over serial % NHS dilutions. Curves were fitted using nonlinear 
regression. CH50, the amount (l) NHS giving 50% hemolysis (K) was calculated by 
plotting a log-log graph of NHS volume vs Y/(1-Y) giving a linear trace [35]. At 50% 
hemolysis, Y/1-Y=1, hence the intercept on the x-axis from this point is K and K 
corresponds to 1 CH50 unit in serum. Statistical significance was evaluated using a 
two-tailed unpaired t test. 
2.7.2 Functional add-back assay 
The effects of TM on complement activity at varying FH concentrations was tested 
by adding the proteins to FH-depleted serum (ΔBH-NHS) prepared as described 
above. TM456 or rbTM was titrated in CFD and added to 1% ΔBH-NHS, a serum 
dilution selected to give 70-80% lysis. FH and FB were added back together with 2% 
ShEA to induce lysis.  
FH/FB-double depleted serum (ΔBH-NHS) is used to assay the ability of factor H to 
regulate the amplification system of the alternative pathway in the presence of 
TM456 or rabbit TM. By adding 1% ΔBH-NHS to serial FH dilutions (0.001-1M) we 
stabilize the alternative pathway; then adding 2% ShEA and 2ug/ml FB with or 
without 2M TM456 or 50nM rbTM in CFD buffer to induce lysis. 
Curves were fitted using nonlinear regression and are expressed as % hemolysis 
over serial factor H concentrations (nM) giving IC50 (inhibition of hemolysis by 50%) 
and maximum response (i.e. complement-mediated cell lysis Max%Lysis). A similar 
unit to CH50 is the FH-H50, which we used to quantitate the activity of FH in BH-
NHS in the presence or absence of TM456 or rbTM.  A FH-H50 unit is the amount of 
functional FH needed to regulate lysis of 50% of antibody- sensitized sheep 
erythrocytes (ShEA) when incubated with 1% BH-NHS.  
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3 Results 
3.1 Molecular analysis of recombinant thrombomodulin variants 
Before commencing with the biochemical analysis, the two commercially available 
human recombinant soluble TM preparations (termed TM1 and TM2), were 
characterized. Molecular weights were confirmed with mass spectrometry (MS); this 
demonstrated a molecular weight for TM1 ~66 kDa and TM2 ~64kDa, the difference 
accounted for by the sequence differences (TM1, Ala19-Ser515 plus 6xHis-tag; TM2, 
Ala19-Ala509) and variable glycosylation for TM from different expression systems. 
Both TM analogs were functional and mediated the activation of protein C (APC) in 
the presence of thrombin and calcium and also significantly reduced the endogenous 
thrombin potential (ETP; the area under the curve) in plasma thrombin generation 
assays (data not shown). 
3.2 Thrombomodulin binds C3b with micromolar and FH with nanomolar 
affinity 
To test binding, TM1 was immobilized on plastic, for affinity analysis TM1 and TM2 
were captured on SPR chips. In order to confirm that indirect SPR surface capture 
did not affect TM capacity to bind ligands, we first analyzed thrombin affinity as a 
positive control. Catalytically inactive thrombin was used to prevent proteolysis 
during analysis. Both TM1 and TM2 bound thrombin with nM affinity (Supplementary 
Figure 1), similar to results for thrombin interaction with the TM analog SolulinTM in 
an equivalent experimental setting [32]. 
There was a several-fold difference in binding affinity for thrombin between TM1 to 
TM2, with TM1 showing 3-5 fold higher affinity to both thrombin molecules (PPACK-
inhibited thrombin: TM1, KD 15.4+/-4.5 nM and TM2, KD 72+/-7.07; inactive S195A 
thrombin: TM1, KD: 19.1+/-1.4 nM and TM2, KD: 49.6+/-2.4 nM; Supplementary 
Figure 1 A and B). There was no statistically significant difference in binding of 
S195A-thrombin versus PPACK-thrombin to either TM1 (p=0.3848) or TM2 
(p=0.0515), confirming published results, where recombinant TM456, bound PPACK-
thrombin compared to active thrombin with the same affinity [36].  
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The direct interaction of CFH and C3b with TM was shown by coprecipitations and 
immunoblotting, and this interaction is increased in the presence of FH [16]; 
however, there is no published knowledge about their respective complement 
binding affinities compared with TMs’ natural ligand thrombin when antibody-
captured rather than on thrombin-sepharose. First, we confirmed binding of our TM 
analogs to human FH in a solid phase ligand binding assay (Figure 1 A). We then 
tested binding by SPR analysis; this yielded binding affinities for TM1 and TM2 with 
FH in the nanomolar range (TM1 KD: 276+/-60 nM and TM2 KD: 114+/-25nM; Fig.  1 
B and C).  
Both TM1 and TM2 also bound fluid-phase C3b with similar affinities (TM1  KD: 
1.13+/-0.09 M and TM2 KD: 1.16+/-0.02 M; Fig. 2 A and B), albeit much more 
weakly than FH binding to TM. When the pre-formed C3b-FH complex was flowed 
over immobilized TM it displayed the highest binding affinity (TM1 KD~ 91 nM and 
TM2 KD~76 nM; Fig. 2 C and D); the data suggest that TM binds the complex better 
(or at least as well) than the individual components. However, from these data we 
cannot deduct whether this is an additive effect or due to binding to a new epitope 
present in the C3b-FH complex. 
While TM1 and TM2 differed in their binding affinities for thrombin and FH, there was 
no difference between these analogs with C3b binding. 
3.3 Thrombomodulin binds immobilized C3b but not C3bBb 
C3b was immobilized on an SPR chip surface and, for some studies, the C3bBb 
convertase was formed in situ on the chip as previously described [37]. TM was 
flowed over densely immobilized C3b and specific binding was observed (Fig. 3 A). 
When TM was flowed over a low density C3b or preformed C3bBb complex, no 
binding was observed (Fig. 3 B); further, flowing TM did not accelerate decay of the 
C3bBb convertase (Fig. 3 B). Together, these data suggest that TM binding C3b 
alone is very weak and that TM cannot bind to or accelerate decay of the 
convertase. 
It has been reported that TM enhances FH cofactor activity [16, 17]. FH co-factor 
activity is mediated by its domains SCR1-4 (short consensus repeat 1, 2, 3 and 4) 
[38], which also promote FH-mediated C3bBb convertase decay. Therefore, we 
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tested whether TM is able to enhance FH-mediated decay of C3bBb.  FH caused 
accelerated decay of C3bBb as expected but there was no significant change in FH-
accelerated decay when a pre-formed FH-TM were flowed, indicating that the 
observed interactions do not impact FH-mediated decay (Fig. 3 C, D). 
3.4 Thrombomodulin regulates complement activity in serum 
The capacity of TM to bind individual complement proteins has been shown.  In 
order to determine whether TM impacts plasma complement activity, we used a 
standard hemolytic assay, and added in TM1 and TM2.  
To be able to add-back a therapeutically relevant concentration, we used available 
data on the therapeutic soluble recombinant TM (ART-123/Recomodulin™) which is 
similar to the recombinant protein analogs used in this work. This agent is used at a 
dose of 380 U/kg;0.06mg/kg (Japanese Ministry of Health, Labour and Welfare) by 
daily intravenous administration for treatment of disseminated intravascular 
coagulation [18]. Plasma levels in patients are ~1500 ng/ml [39], while the highest 
concentration achieved with no bleeding event in the non-clinical toxicology studies 
was 5400  ng/mL with a therapeutic range of TM 300–5400  ng/mL [40]. We used 
the concentration of 5400  ng/mL (83~104nM) in our studies. 
NHS was spiked with TM to achieve a final concentration of 100 nM and compared 
to untreated NHS in a hemolysis assay (Fig. 4). TM1 and TM2 (each at 100nM in 
undiluted NHS) significantly reduced complement activity in NHS by 19% and 16% 
respectively (TM1 in NHS CH50 ~ 1.53+/-0.04 compared to NHS alone CH50 ~ 1.25 
+/- 0.05, P~0.008, Fig. 4A and B and TM2 in NHS CH50 ~ 1.75 +/- 0.06 compared to 
NHS CH50 ~ 1.48 +/- 0.02, P~0.011, Fig. 4C and 4D). These relatively small 
changes in CH50 were replicated in several assays executed on different days with 
fresh NHS and ShEA (data summarized in Fig. 4E). Absolute CH50 values vary from 
day-to-day; however, each individual measurement reproduces the significant 
difference between NHS titration curve with or without TM. The data suggest that TM 
at doses used for therapy has a small but consistent inhibitory effect on serum 
complement activity.  
3.5 Complement regulation by human recombinant TM456 fragment 
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Thrombin binds to the EGF5-6 domains of TM [41], which comprise the minimum 
functional  domain involved in anticoagulant activity via a thrombin-mediated protein 
C activation mechanism [42]. To see whether thrombin-binding sites of TM were 
important for complement regulating activity we tested the TM456 fragment, 
comprising EGF456 only.  
In a solid-phase binding assay, we first confirmed the binding interaction of 
immobilized TM456 to FH (Figure 5 A). SPR confirmation of binding was attempted 
but capture of the TM456 on the antibody surface was inefficient. We could further 
show that TM456 regulates complement lysis in a dose-dependent manner when 
added back to BH-NHS alongside FB and FH. In the absence of TM456, 85% lysis 
was achieved, whereas in the presence of the maximum dose of 2M TM456, lysis 
was reduced to 61% (Figure 5 B).  
FH-H50 was 15 +/-4nM in the presence of TM456 and 41 +/-3nM in its absence, 
showing that in the presence of TM456, less FH is needed to reduce lysis to 50% 
(Figure 5 C). A clear reduction in the maximum response (i.e. complement-mediated 
maximum cell lysis; Max%Lysis) was observed when titrating FH in the presence 
(Max%Lysis 60.9+/-2.8) compared to absence of TM456 (Max%Lysis, 73.6+/-0.5, 
p=0.018). TM456 inhibited complement activity even in the absence of FH, implying 
that TM456-mediated complement regulation is not exclusively via interaction with 
FH (Figure 5 D).  
3.6 Complement regulation by purified rabbit thrombomodulin 
In order to test whether native, purified TM expressed complement regulatory activity  
we used purified rabbit thrombomodulin (rbTM), which has been traditionally used as 
a human analog with similar function [43] as the isolation of human thrombomodulin 
from for instance placental tissue was not feasible. 
In a solid-phase binding assay, we first confirmed the binding interaction of 
immobilized rbTM to human FH (Figure 6 A). We further showed that rbTM also 
regulates complement lysis in a dose-dependent manner when added back to BH-
NHS alongside FB and FH (Figure 6 B).  
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FH-H50 was 59 +/-2nM in the presence of rbTM and 134 +/-3nM in its absence, 
showing that in the presence of rbTM, less FH is needed to reduce lysis to 50% 
(Figure 6 C, p<0.0001). A clear reduction in the maximum response (Max%Lysis) was 
observed when titrating FH in the presence (Max%Lysis 87.5+/-0.4) compared to 
absence of rbTM (Max%Lysis, 102+/-2.5, p=0.0005). As seen with TM456, rbTM 
inhibited complement activity even in the absence of FH (Figure 6 D).  
4. Discussion 
TM expression on endothelial cells (ECs) aids the maintenance of  a continuous 
barrier along the vasculature through coagulation regulation via its interaction with 
thrombin and activation of protein C [44]. The endothelium is also a target for 
complement [45] and upon activation and generation of C5a, induction of tissue 
factor (TF) has been observed [46], linking both complement and coagulation to sites 
of endothelial dysfunction. TMs’ role in complement regulation is bi-fold, it aids the 
generation of TAFIa [9] which in turn inactivates complement C3a and C5a [10], and 
it further promotes the inactivation of iC3b by enhancing FH-cofactor activity [16, 17].  
Normal vascular endothelium expresses an anti-inflammatory phenotype and does 
not support complement activation in the absence of vascular damage [47]. 
Endothelial FH binding via polyanionic markers such as sialic acid and sulphated 
polysaccharides, such as heparin sulfate plays a crucial role in ‘self’ (healthy) versus 
‘non-self’ (damaged) recognition [48, 49]. FH concentration in plasma can range as 
much 116–562 μg/ml (0.75-3.6 M, 115 kDa) depending on genetic and 
environmental factors [50, 51] and FH binds C3b [37, 52] with an affinity of ~1M. 
Surface-bound FH concentration is unknown, however, a several fold higher affinity 
of FH for C3b was observed on host cells in the presence of  
polyanions/polysaccharides on the surface [53], supporting a role for FH regulating 
complement activation on the surface in the event of opsonisation. 
Here we found that TM binds FH with nanomolar affinity, and also binds C3b albeit 
with relatively weak micromolar affinity; importantly, TM displayed a significantly 
increased affinity for the C3b-FH complex. Similar to the observations that the 
presence of polyanions increases C3b-H affinity [53], TM may be supporting the 
attachment of FH to the endothelium – enhanced in the presence of complement 
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activation and C3b opsonisation (C3b-FH). This might aid FH localization to the 
endothelial surface, providing vascular protection and supporting the discrimination 
of host endothelium from complement-activating foreign cells.  
We further showed that despite TM’s ability to bind to C3b, FH and the C3b-FH 
complex, it neither bound C3b within the C3bBb convertase complex nor decayed 
the C3bBb complex; this may be due to different binding sites exposed in C3b-FH 
versus C3bBb complex. Indeed, a steric clash between FH (SCR1-4) and Bb when 
aligning C3b-FH and C3bBb was shown in a structural study [54]. FH decay activity 
(i.e. displacing Bb) is likely located within SCR1-2 of its structure [54], and FH 
cofactor activity is largely lost without SCR1, implying that the interaction of SCR1 
and SCR2 with C3b is crucial for FH regulatory activities [38]. TM binding to FH 
influences its cofactor but not decay activity, one can speculate that it binds directly 
within a region that is involved in its regulatory activity (i.e. SCR1-4) or indirectly 
influences these by affecting the overall structure of the C3b-FH complex. 
To directly compare the complement-TM interaction with its natural ligand thrombin, 
we performed affinity analysis with catalytically inactive thrombin molecules. 
Thrombin affinities for both TM analogs was several-fold higher than to FH and FH-
C3b, indicating that in the event of thrombin generation, the TM-thrombin complex 
formation is prevalent if FH and/or FH-C3b share the same binding sites on TM as 
suggested by TM456, a thrombin binding site, having complement regulatory activity. 
TM analogs differed in their affinity for binding FH and thrombin indicating that the 
expression system, folding and glycosylation impact ligand binding [55]. As the TM 
analogs are of similar molecular weight, it is unlikely the degree of glycosylation is 
causing the differences in affinity; rather, the type of attached glycans likely 
influences affinity. Interestingly, no difference was shown for C3b, therefore C3b may 
involve different binding sites to FH and thrombin for TM. 
We next tested the effect of TM on systemic complement activity. In standard 
hemolysis assays, we showed that full length recombinant soluble TM inhibits 
complement activity at a therapeutically relevant concentration [40]. The effect of TM 
analogs was small, but robustly reproducible. The amount of complement regulation 
observed, even though it is little, might potentially be effective in the context of HUS 
and aHUS. We have previously shown that even a small impact on complement 
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activity can have a significant effect over time [56]; so suggest that this effect of TM 
is functionally and physiologically relevant. TM influences fluid phase regulation of 
complement and also binds opsonised surfaces, as demonstrated in real time by 
binding a densely opsonised C3b surface in vitro. As a consequence we suggest that 
it is important to determine the hemolytic complement activity in individuals before 
and during treatment with Recomodulin™ in future clinical trials, This is of particular 
importance in studies investigating the role of soluble TM in patients with hemolytic 
uremic syndrome (HUS) [20, 57], a condition caused by complement dysregulation. 
Here, a therapeutic that can efficiently regulate both coagulation and complement 
may be of particular value.  
aHUS-associated mutations in TM impacting FH-mediated inactivation of C3b were 
identified in the C-type lectin-like domain of TM and increased complement activation 
was found in the TMLeD/LeD mice [39], which shows that this domain is important 
for complement binding interaction. Further TM mutations were located within the 
serine/threonine-rich region, also affecting FH-cofactor activity, likely another site of 
complement C3b and FH binding. Recombinant TM456 has similar anticoagulant 
activity to full length TM, although its short half-life limits its therapeutic application 
[58]. Additionally, it appears that the EGF456 domains in TM are also of importance 
to complement regulation. In functional assays, we tested a recombinant fragment of 
TM456, including the thrombin binding sites EGF5-6. We found that TM456 reduces 
complement activity in a dose-dependent manner in serum and when titrating FH, 
further supporting the idea that these domains are involved in complement 
regulation. This supports the speculation that complement, and particularly regulator 
FH, binds TM via multiple binding sites including EGF456, especially since the 
concentration of TM456 in the assay required to see an effect was several fold 
higher than for full-length TM.  
Interestingly, we observed TM456 regulation also in the absence of FH, pointing to 
another mechanism, possibly via the interaction with C4bp, a CP regulator, which 
has been previously identified to bind TM [16]. Controversially, a recent report stated 
the AP enhancing activity of TM by increasing C3 convertase mediated cleavage of 
C3 into C3b, however, at non-physiological TM concentrations [17]. 
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Therefore, the complement-regulatory activity of TM is mediated through binding 
interactions of complement C3b and FH with the C-type lectin-like domain, EGF456 
and the serine/threonine-rich region, the latter being the site of chondroitin sulfate 
attachment, whose presence not only enhances the TM interaction with thrombin 
[59] but also has been shown to bind both FH and C4bp in vitro [60]. 
To confirm our observations obtained with human recombinant TM with natural 
purified TM, we utilized TM from rabbit lung tissue to confirm the above findings of 
complement regulation in normal human serum and when titrating FH, also 
reproducing the finding that in the absence of FH, complement regulation remains. 
The complex interaction of TM in the presence and absence of FH with C4bp or any 
other complement molecule is part of future investigations.  
 
5. Conclusions 
Our work shows the contribution of TM in FH mediated host protection through the 
high affinity interaction with FH and the FH-C3b complex. These results further 
support the potential of soluble TM to exert complement regulatory activity in serum.  
Additionally, since regulation can be observed by TM456 in the absence of FH, it 
becomes clear that TM inhibits complement hemolytic activity in serum via FH 
dependent and independent mechanisms. And that the cross-talk between TM and 
complement is more complex involving yet another complement protein. 
In conclusion, TM may display a dual functional role; in addition to its classical role in 
binding thrombin to limit clot development it also supports FH ‘policing’ of the 
endothelium, facilitating down-regulation of complement activation in the event of 
FH-C3b formation. 
Our data imply that soluble TM is a potential therapeutic option in conditions where 
both coagulation and complement are dysregulated. This may be of particular 
importance in conditions where surface dysregulation of complement in addition to 
coagulopathy is a disease hallmark, such as in HUS or aHUS.  
As TM analogs from different expression systems differ in their interaction with both 
thrombin and FH, this may influence soluble TM efficacy in regulating coagulation 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
18 
 
and complement in vivo. Therapeutic TM should therefore be characterized for 
complement regulatory activity. 
Addendum 
M. Heurich designed and performed research, analyzed and interpreted the data and 
wrote the paper; R. J.S. Preston contributed analytical tools, analyzed data and 
editing the manuscript; V. B. O’Donnell, and B.P. Morgan contributed analytical tools, 
interpretation of data and editing the manuscript. P.W. Collins contributed to 
research design, interpretation of data, revising the intellectual content and co-wrote 
the paper. All authors approved the paper. 
Acknowledgments 
We thank Prof. C.L. Harris (Cardiff, United Kingdom) for kindly providing access to 
equipment and reading and editing the manuscript. We thank Prof. J.A. Huntington 
(Cambridge, United Kingdom) for the generous contribution of reagents S195A 
Thrombin and TM456. We thank Prof. S. Rodríguez de Cordoba (Madrid, Spain) for 
the kind gift of antibody mab 35H9. We thank Dr Caroline O'Hagan for technical 
support with the FH ELISA.  This work was supported the National Institute for Social 
Care and Health Research Wales, UK (NISCHR, 2012-2016; M.H. & P.W.C) and the 
Morgan E. Williams Fund (M.H., 2014). 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
19 
 
References 
[1] Owen WG, Esmon CT. Functional properties of an endothelial cell cofactor for thrombin-catalyzed 
activation of protein C. The Journal of biological chemistry. 1981;256:5532-5. 
[2] Esmon CT, Owen WG. The discovery of thrombomodulin. Journal of thrombosis and haemostasis 
: JTH. 2004;2:209-13. 
[3] Boehme MW, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, et al. Release of 
thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo 
and in vitro studies. Immunology. 1996;87:134-40. 
[4] Yamamoto S, Mizoguchi T, Tamaki T, Ohkuchi M, Kimura S, Aoki N. Urinary thrombomodulin, its 
isolation and characterization. Journal of biochemistry. 1993;113:433-40. 
[5] Faust SN, Heyderman RS, Levin M. Coagulation in severe sepsis: a central role for 
thrombomodulin and activated protein C. Critical care medicine. 2001;29:S62-7; discussion S7-8. 
[6] Sawada K, Yamamoto H, Yago H, Suehiro S. A simple assay to detect endothelial cell injury; 
measurement of released thrombomodulin from cells. Experimental and molecular pathology. 
1992;57:116-23. 
[7] Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and 
inflammation. Journal of thrombosis and haemostasis : JTH. 2011;9 Suppl 1:168-73. 
[8] Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin 
inhibits both thrombin-catalyzed fibrin formation and factor V activation. The Journal of biological 
chemistry. 1982;257:7944-7. 
[9] Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation 
and fibrinolytic cascades through the thrombin-thrombomodulin complex. The Journal of biological 
chemistry. 1996;271:16603-8. 
[10] Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by 
carboxypeptidase R and carboxypeptidase N. Microbiology and immunology. 2002;46:131-4. 
[11] Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: 
strangers or partners in crime? Trends in immunology. 2007;28:184-92. 
[12] Conway EM. Reincarnation of ancient links between coagulation and complement. Journal of 
thrombosis and haemostasis : JTH. 2015;13 Suppl 1:S121-32. 
[13] Walport MJ. Complement. First of two parts. The New England journal of medicine. 
2001;344:1058-66. 
[14] Walport MJ. Complement. Second of two parts. The New England journal of medicine. 
2001;344:1140-4. 
[15] Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: isolation, 
characterization, and demonstration of an absolute requirement for the serum protein beta1H for 
cleavage of C3b and C4b in solution. The Journal of experimental medicine. 1977;146:257-70. 
[16] Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin 
mutations in atypical hemolytic-uremic syndrome. The New England journal of medicine. 
2009;361:345-57. 
[17] Tateishi K, Imaoka M, Matsushita M. Dual modulating functions of thrombomodulin in the 
alternative complement pathway. Bioscience trends. 2016. 
[18] Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of 
recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: 
results of a phase III, randomized, double-blind clinical trial. Journal of thrombosis and haemostasis : 
JTH. 2007;5:31-41. 
[19] Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-
blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human 
soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular 
coagulation. Critical care medicine. 2013;41:2069-79. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
 
[20] Yada N, Fujioka M, Bennett CL, Inoki K, Miki T, Watanabe A, et al. STEC:O111-HUS complicated 
by acute encephalopathy in a young girl was successfully treated with a set of hemodiafiltration, 
steroid pulse, and soluble thrombomodulin under plasma exchange. Clinical case reports. 
2015;3:208-12. 
[21] Mizuno H, Minouchi K, Aoyama S, Hinoue Y. Successful treatment of enterohemorrhagic 
Escherichia coli O111-induced hemolytic-uremic syndrome and acute encephalopathy. Nihon 
Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. 2015;112:1309-16. 
[22] Udagawa T, Motoyoshi Y, Matsumura Y, Takei A, Ariji S, Ito E, et al. Effect of eculizumab and 
recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical 
hemolytic uremic syndrome due to anti-factor H autoantibodies. CEN Case Rep. 2014;3:110-7. 
[23] Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH. Mutations in alternative pathway 
complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 
2010;31:E1445-E60. 
[24] Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative Role of Genetic 
Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. 
Clin J Am Soc Nephrol. 2010;5:1844-59. 
[25] Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic 
syndrome (aHUS). Semin Thromb Hemost. 2014;40:422-30. 
[26] Schramm EC, Roumenina L, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, et al. Functional 
mapping of the interactions between complement C3 and regulatory proteins using atypical 
hemolytic uremic syndrome-associated mutations. Blood. 2015:blood-2014-10-609073. 
[27] Martinez-Barricarte R, Heurich M, Lopez-Perrote A, Tortajada A, Pinto S, Lopez-Trascasa M, et 
al. The molecular and structural bases for the association of complement C3 mutations with atypical 
hemolytic uremic syndrome. Molecular immunology. 2015;66:263-73. 
[28] Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, et al. Anti-Factor H 
autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 
2005;16:555-63. 
[29] Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, et al. Factor I 
autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an 
epiphenomenon? Clin J Am Soc Nephrol. 2012;7:417-26. 
[30] Huntington JA, Esmon CT. The molecular basis of thrombin allostery revealed by a 1.8 A 
structure of the "slow" form. Structure (London, England : 1993). 2003;11:469-79. 
[31] Li W, Adams TE, Nangalia J, Esmon CT, Huntington JA. Molecular basis of thrombin recognition 
by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex. Proc Natl 
Acad Sci U S A. 2008;105:4661-6. 
[32] Light DR, Glaser CB, Betts M, Blasko E, Campbell E, Clarke JH, et al. The interaction of 
thrombomodulin with Ca2+. European journal of biochemistry / FEBS. 1999;262:522-33. 
[33] Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, Rumennik G, Seto M, et al. Structural basis for the 
anticoagulant activity of the thrombin-thrombomodulin complex. Nature. 2000;404:518-25. 
[34] Mayer MM. Complement and complement fixation. In: Mayer EKaMM, editor. Experimental 
immunochemistry. Springfield, Ill: C. C. Thomas; 1961. p. 133-240. 
[35] Complement methods and protocols: Totowa, N.J. : Humana Press, [2000] ©2000; 2000. 
[36] Baerga-Ortiz A, Rezaie AR, Komives EA. Electrostatic dependence of the thrombin-
thrombomodulin interaction1. Journal of Molecular Biology. 2000;296:651-8. 
[37] Heurich M, Martínez-Barricarte R, Francis NJ, Roberts DL, Rodríguez de Córdoba S, Morgan BP, 
et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic 
complement activity and disease risk. Proc Natl Acad Sci U S A. 2011;108:8761-6. 
[38] Gordon DL, Kaufman RM, Blackmore TK, Kwong J, Lublin DM. Identification of complement 
regulatory domains in human factor H. Journal of immunology (Baltimore, Md : 1950). 
1995;155:348-56. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
21 
 
[39] Moll S, Lindley C, Pescatore S, Morrison D, Tsuruta K, Mohri M, et al. Phase I study of a novel 
recombinant human soluble thrombomodulin, ART-123. Journal of Thrombosis and Haemostasis. 
2004;2:1745-51. 
[40] Mouksassi M-S, Marier J-F, Bax L, Osawa Y, Tsuruta K. Population pharmacokinetic analysis of 
thrombomodulin alfa to support dosing rationale in patients with renal impairment. Clinical 
Pharmacology in Drug Development. 2015;4:210-7. 
[41] Sadler JE, Lentz SR, Sheehan JP, Tsiang M, Wu Q. Structure-function relationships of the 
thrombin-thrombomodulin interaction. Haemostasis. 1993;23 Suppl 1:183-93. 
[42] Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive 
epidermal growth factor-like structures of human thrombomodulin comprise the minimum 
functional domain for protein C-activating cofactor activity and anticoagulant activity. The Journal of 
biological chemistry. 1989;264:10351-3. 
[43] Salem HH, Maruyama I, Ishii H, Majerus PW. Isolation and characterization of thrombomodulin 
from human placenta. The Journal of biological chemistry. 1984;259:12246-51. 
[44] Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. 
The Journal of biological chemistry. 1989;264:4743-6. 
[45] Bossi F, Bulla R, Tedesco F. Endothelial cells are a target of both complement and kinin system. 
International immunopharmacology. 2008;8:143-7. 
[46] Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity 
on endothelial cells. Thrombosis and haemostasis. 1997;77:394-8. 
[47] Hindmarsh EJ, Marks RM. Complement activation occurs on subendothelial extracellular matrix 
in vitro and is initiated by retraction or removal of overlying endothelial cells. Journal of immunology 
(Baltimore, Md : 1950). 1998;160:6128-36. 
[48] Jokiranta TS, Cheng ZZ, Seeberger H, Jozsi M, Heinen S, Noris M, et al. Binding of complement 
factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. The 
American journal of pathology. 2005;167:1173-81. 
[49] Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP, et al. Structural basis 
for engagement by complement factor H of C3b on a self surface. Nature structural & molecular 
biology. 2011;18:463-70. 
[50] Hakobyan S, Tortajada A, Harris CL, de Córdoba SR, Morgan BP. Variant-specific quantification of 
factor H in plasma reveals null alleles associated with atypical hemolytic uremic syndrome. Kidney 
international. 2010;78:782-8. 
[51] Esparza-Gordillo J, Soria JM, Buil A, Almasy L, Blangero J, Fontcuberta J, et al. Genetic and 
environmental factors influencing the human factor H plasma levels. Immunogenetics. 2004;56:77-
82. 
[52] Tortajada A. The disease-protective complement factor H allotypic variant Ile62 shows increased 
binding affinity for C3b and enhanced cofactor activity. 2009;18:3452-61. 
[53] Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative 
pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl 
Acad Sci U S A. 1990;87:3982-6. 
[54] Wu J, Wu YQ, Ricklin D, Janssen BJC, Lambris JD, Gros P. Structure of C3b-factor H and 
implications for host protection by complement regulators. Nat Immunol. 2009;10:728-33. 
[55] Shental-Bechor D, Levy Y. Effect of glycosylation on protein folding: A close look at 
thermodynamic stabilization. Proceedings of the National Academy of Sciences. 2008;105:8256-61. 
[56] Harris CL, Heurich M, Cordoba SRd, Morgan BP. The complotype: dictating risk for inflammation 
and infection. Trends in immunology. 2012;33:513-21. 
[57] Honda T, Ogata S, Mineo E, Nagamori Y, Nakamura S, Bando Y, et al. A novel strategy for 
hemolytic uremic syndrome: successful treatment with thrombomodulin alpha. Pediatrics. 
2013;131:e928-33. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
22 
 
[58] Suzuki M, Mohri M, Yamamoto S. In vitro anticoagulant properties of a minimum functional 
fragment of human thrombomodulin and in vivo demonstration of its benefit as an anticoagulant in 
extracorporeal circulation using a monkey model. Thrombosis and haemostasis. 1998;79:417-22. 
[59] Sadler JE. Thrombomodulin structure and function. Thrombosis and haemostasis. 1997;78:392-
5. 
[60] Hamad OA, Nilsson PH, Lasaosa M, Ricklin D, Lambris JD, Nilsson B, et al. Contribution of 
chondroitin sulfate A to the binding of complement proteins to activated platelets. PloS one. 
2010;5:e12889. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
23 
 
Figure legends 
 
Figure 1. Binding affinity of FH to recombinant human TM analogs. (A) A ligand 
binding assay confirmed the binding of FH (1,2 and 5 ug/ml) to immobilized TM1. 
Data points represent mean ± SD of triplicate determinations (error bars depicted for 
each point) within one binding assay.  
(B) FH was flowed over polyclonal antibody-captured recombinant human 
thrombomodulin TM1 and (C) TM2 at concentrations between 1.55 nM and 1.6 M 
and equilibrium binding response was measured.  Affinity (KD) was determined by 
steady-state analysis in duplicate for TM1 KD 276+/-60 nM and TM2 KD 114+/-25nM 
(mean +/- SD, n=2).  
 
Figure 2. Binding affinity of C3b and C3b-FH to recombinant human 
TM analogs. C3b was flowed over (A) TM1 and (B) TM2 at concentrations between 
4.4 nM and 5 M and affinity was determined by 1:1 binding model for TM1 KD 
1.13+/-0.09 M and TM2 KD 1.16+/-0.02 M (mean +/- SD, n=2). Preformed 
equimolar C3b-FH complex was flowed over (C) TM1 and (D) TM2 at concentrations 
between 7.8 nM and 800 nM and affinity was determined by 1:1 binding model for 
TM1 KD~91 nM and TM2 KD~76 nM (n=1).  
Figure 3. TM interaction with C3b and C3bBb. (A) 1M TM was flowed over 6000 
RU thioester-deposited C3b. (B) 200 nM TM1 was flowed over a preformed C3bBb 
convertase (black line, injection of TM1 indicated by arrow) on a 1000RU C3b 
surface. (C) As indicated by arrows, 100 nM FH was flowed over a preformed C3bBb 
convertase in the absence (black dashed line) or presence (grey line) of 200 nM TM. 
(D) To illustrate FH-mediated C3bBb decay, FH binding to the C3b surface alone 
(Inset) was subtracted from the C3bBb sensorgram.  
Figure 4. TM regulates complement activity in serum.  Activated sheep 
erythrocytes (ShEA) were incubated with normal human serum (NHS) spiked with 
100 nM human recombinant TM (circles) compared to NHS alone (squares) and lysis 
was developed. Data points represent mean ± SD of three determinations (error bars 
depicted for each point). Lysis was calculated by measuring hemoglobin release as a 
percentage of the controls. Nonlinear regression curves (A, C) and CH50 log-log plot 
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(B, D) are shown for TM1 (A,B) and TM2 (C,D), respectively. (E) Summary of CH50 
values (NHS volume in l at 50% hemolysis) each for TM1 (n=2) and TM2 (n=2) in 
NHS compared to NHS only and corresponding p values analyzed in independent 
assays. P values were calculated using a two-tailed unpaired t test.  
Figure 5. Complement regulation by human recombinant TM456 fragment. (A) 
TM456 binding assay confirmed the binding of FH (1,2 and 5 g/ml) to immobilized 
TM456. Data points represent mean ± SD of triplicate determinations (error bars 
depicted for each point) within one binding assay. (B) Serial dilution of TM456 
(0.125-2M) added to 1% H-NHS with constant FB and FH and ShEA to develop 
lysis in CFD. In the absence of TM456, 85% lysis was achieved by 1% H-NHS, 
whereas the maximum dose of 2M reduced lysis to 61%. (C) Serial dilutions of FH 
(0.001-1M) was added to TM456-sufficient (2M) or deficient 1% BH-NHS and 
lysis developed in ShEA, with FB in CFD.  FH-H50 was 15 +/-4nM in the presence of 
TM456 (circles) and 41 +/-3nM (squares) in its absence (p=0.018). (D) The 
maximum response (% Lysis) was reduced for TM456-suffient 1% BH-NHS 
(circles, Max%Lysis 60.9+/-2.8) compared to 1% BH-NHS alone (squares, Max%Lysis, 
73.6+/-0.5, p=0.018). Data points represent mean ± SD of three determinations 
(error bars depicted for each point, the assay was repeated twice with identical 
results). 
Figure 6. Complement regulation by purified rabbit TM 
 (A) A ligand binding assay confirmed the binding of FH (1, 2 and 5 g/ml) to 
immobilized rbTM. Data points represent mean ± SD of triplicate determinations 
(error bars depicted for each point) within one binding assay. (B) Serial dilution of 
rbTM (3-200 nM) with FB and FH were added to 1% H-NHS and ShEA to develop 
lysis in CFD. (C) Serial dilutions of FH (0.0019-2 M) were added to rbTM-sufficient 
(50 nM) or deficient 1% BH-NHS and lysis developed in ShEA with FB in CFD.  FH-
H50 was 59 +/-2nM in the presence of rbTM (circles) and 134 +/-3nM (squares) in its 
absence (p<0.0001). (D) The maximum response (% Lysis) was reduced for rbTM-
sufficient 1% BH-NHS (circles, Max%Lysis 87.5+/-0.4) compared to 1% BH-NHS 
alone (squares, Max%Lysis, 102+/-2.5, p=0.0005). Data points represent mean ± SD of 
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three determinations (error bars depicted for each point, the assay was repeated 
twice with identical results). 
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